This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2014 Jan;311(4):361-3.

doi: 10.1001/jama.2013.283946.

Opening the FDA black box

Steven N Goodman¹, Rita F Redberg²

Affiliations

PMID: 24449313
DOI: 10.1001/jama.2013.283946

Editorial

Opening the FDA black box

Steven N Goodman et al. JAMA. 2014 Jan.

. 2014 Jan;311(4):361-3.

doi: 10.1001/jama.2013.283946.

Authors

Steven N Goodman¹, Rita F Redberg²

Affiliations

¹ Stanford University, Stanford, California.
² University of California, San Francisco, and Editor, JAMA Internal Medicine.

PMID: 24449313
DOI: 10.1001/jama.2013.283946

No abstract available

PubMed Disclaimer

Comment on

Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.
Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS. Downing NS, et al. JAMA. 2014 Jan 22-29;311(4):368-77. doi: 10.1001/jama.2013.282034. JAMA. 2014. PMID: 24449315 Free PMC article.
Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
Sacks LV, Shamsuddin HH, Yasinskaya YI, Bouri K, Lanthier ML, Sherman RE. Sacks LV, et al. JAMA. 2014 Jan 22-29;311(4):378-84. doi: 10.1001/jama.2013.282542. JAMA. 2014. PMID: 24449316
FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012.
Rome BN, Kramer DB, Kesselheim AS. Rome BN, et al. JAMA. 2014 Jan 22-29;311(4):385-91. doi: 10.1001/jama.2013.284986. JAMA. 2014. PMID: 24449317 Free PMC article.

Similar articles

Quality of evidence behind FDA approvals varies widely.
McCarthy M. McCarthy M. BMJ. 2014 Jan 27;348:g1075. doi: 10.1136/bmj.g1075. BMJ. 2014. PMID: 24470635 No abstract available.
Building comparative efficacy and tolerability into the FDA approval process.
O'Connor AB. O'Connor AB. JAMA. 2010 Mar 10;303(10):979-80. doi: 10.1001/jama.2010.257. JAMA. 2010. PMID: 20215612 No abstract available.
Cardiac resynchronization therapy for mild congestive heart failure.
[No authors listed] [No authors listed] Technol Eval Cent Assess Program Exec Summ. 2010 Apr;24(8):1-5. Technol Eval Cent Assess Program Exec Summ. 2010. PMID: 20575185 No abstract available.
Critical appraisal of the recent US FDA approval for earlier DBS intervention.
Cabrera LY, Goudreau J, Sidiropoulos C. Cabrera LY, et al. Neurology. 2018 Jul 17;91(3):133-136. doi: 10.1212/WNL.0000000000005829. Epub 2018 Jun 13. Neurology. 2018. PMID: 29898975 Review.
FDA Town Hall at CRT 2017: Current status and future endeavors in cardiovascular devices.
Buchanan KD, Alraies MC, Waksman R. Buchanan KD, et al. Cardiovasc Revasc Med. 2017 Jun;18(4):308-311. doi: 10.1016/j.carrev.2017.04.015. Cardiovasc Revasc Med. 2017. PMID: 28577795 Review. No abstract available.

See all similar articles

Cited by

ArthroplastyWatch.com three-year follow-up: where do we stand now?
Alriksson-Schmidt A, Ranstam J, Robertsson O, Lidgren L. Alriksson-Schmidt A, et al. EFORT Open Rev. 2017 Mar 13;1(4):81-82. doi: 10.1302/2058-5241.1.160029. eCollection 2016 Apr. EFORT Open Rev. 2017. PMID: 28461932 Free PMC article. No abstract available.
How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?
Samuel AM, Rathi VK, Grauer JN, Ross JS. Samuel AM, et al. Clin Orthop Relat Res. 2016 Apr;474(4):1053-68. doi: 10.1007/s11999-015-4634-x. Epub 2015 Nov 19. Clin Orthop Relat Res. 2016. PMID: 26584802 Free PMC article.
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report.
Martin PJ, Lee SJ, Przepiorka D, Horowitz MM, Koreth J, Vogelsang GB, Walker I, Carpenter PA, Griffith LM, Akpek G, Mohty M, Wolff D, Pavletic SZ, Cutler CS. Martin PJ, et al. Biol Blood Marrow Transplant. 2015 Aug;21(8):1343-59. doi: 10.1016/j.bbmt.2015.05.004. Epub 2015 May 15. Biol Blood Marrow Transplant. 2015. PMID: 25985921 Free PMC article. Review.
Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities.
Sharan S, Woo S. Sharan S, et al. Front Pharmacol. 2015 Feb 20;6:33. doi: 10.3389/fphar.2015.00033. eCollection 2015. Front Pharmacol. 2015. PMID: 25750626 Free PMC article.
Approval of high-risk medical devices in the US: implications for clinical cardiology.
Rome BN, Kramer DB, Kesselheim AS. Rome BN, et al. Curr Cardiol Rep. 2014;16(6):489. doi: 10.1007/s11886-014-0489-0. Curr Cardiol Rep. 2014. PMID: 24760423 Free PMC article. Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information